Which statement about the use of Gentamicin in MRSA endocarditis is correct?

Which statement about the use of Gentamicin in MRSA endocarditis is correct?

• A. It should always be used with vancomycin.
• B. It should be used only when susceptible.
• C. It should replace vancomycin entirely.
• D. It is added if the organism is susceptible.

Answer: (D)

The main idea is that gentamicin serves as an adjunct in MRSA endocarditis only when the isolate is susceptible to it, not as a universal add-on or a replacement for another drug. When the MRSA strain tests susceptible to gentamicin, adding this antibiotic in the early phase can yield a synergistic bactericidal effect alongside the primary therapy (often vancomycin or a similar agent). Because aminoglycosides carry risks of kidney injury and ototoxicity, the use should be limited to a short course and guided by susceptibility results and careful monitoring. If the organism isn’t susceptible to gentamicin, it’s not used. It’s not about replacing vancomycin, but about adding gentamicin only when the organism is susceptible. That’s why the statement that it is added if the organism is susceptible is the best choice.

The main idea is that gentamicin serves as an adjunct in MRSA endocarditis only when the isolate is susceptible to it, not as a universal add-on or a replacement for another drug. When the MRSA strain tests susceptible to gentamicin, adding this antibiotic in the early phase can yield a synergistic bactericidal effect alongside the primary therapy (often vancomycin or a similar agent). Because aminoglycosides carry risks of kidney injury and ototoxicity, the use should be limited to a short course and guided by susceptibility results and careful monitoring. If the organism isn’t susceptible to gentamicin, it’s not used. It’s not about replacing vancomycin, but about adding gentamicin only when the organism is susceptible. That’s why the statement that it is added if the organism is susceptible is the best choice.